Cargando…
Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy
Acute myeloid leukemia (AML) is an aggressive malignancy, and many elderly/unfit patients cannot receive intensive and potentially curative therapy. These patients receive low-toxicity disease-stabilizing treatment. The combination of all-trans retinoic acid (ATRA) and the histone deacetylase inhibi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829623/ https://www.ncbi.nlm.nih.gov/pubmed/31658693 http://dx.doi.org/10.3390/cells8101229 |
_version_ | 1783465600824115200 |
---|---|
author | Grønningsæter, Ida Sofie Fredly, Hanne Kristin Gjertsen, Bjørn Tore Hatfield, Kimberley Joanne Bruserud, Øystein |
author_facet | Grønningsæter, Ida Sofie Fredly, Hanne Kristin Gjertsen, Bjørn Tore Hatfield, Kimberley Joanne Bruserud, Øystein |
author_sort | Grønningsæter, Ida Sofie |
collection | PubMed |
description | Acute myeloid leukemia (AML) is an aggressive malignancy, and many elderly/unfit patients cannot receive intensive and potentially curative therapy. These patients receive low-toxicity disease-stabilizing treatment. The combination of all-trans retinoic acid (ATRA) and the histone deacetylase inhibitor valproic acid can stabilize the disease for a subset of such patients. We performed untargeted serum metabolomic profiling for 44 AML patients receiving treatment based on ATRA and valproic acid combined with low-dose cytotoxic drugs (cytarabine, hydroxyurea, 6-mercaptopurin) which identified 886 metabolites. When comparing pretreatment samples from responders and non-responders, metabolites mainly belonging to amino acid and lipid (i.e., fatty acid) pathways were altered. Furthermore, patients with rapidly progressive disease showed an extensively altered lipid metabolism. Both ATRA and valproic acid monotherapy also altered the amino acid and lipid metabolite profiles; however, these changes were only highly significant for valproic acid treatment. Twenty-three metabolites were significantly altered by seven-day valproic acid treatment (p < 0.05, q < 0.05), where the majority of altered metabolites belonged to lipid (especially fatty acid metabolism) and amino acid pathways, including several carnitines. These metabolomic effects, and especially the effects on lipid metabolism, may be important for the antileukemic and epigenetic effects of this treatment. |
format | Online Article Text |
id | pubmed-6829623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68296232019-11-18 Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy Grønningsæter, Ida Sofie Fredly, Hanne Kristin Gjertsen, Bjørn Tore Hatfield, Kimberley Joanne Bruserud, Øystein Cells Article Acute myeloid leukemia (AML) is an aggressive malignancy, and many elderly/unfit patients cannot receive intensive and potentially curative therapy. These patients receive low-toxicity disease-stabilizing treatment. The combination of all-trans retinoic acid (ATRA) and the histone deacetylase inhibitor valproic acid can stabilize the disease for a subset of such patients. We performed untargeted serum metabolomic profiling for 44 AML patients receiving treatment based on ATRA and valproic acid combined with low-dose cytotoxic drugs (cytarabine, hydroxyurea, 6-mercaptopurin) which identified 886 metabolites. When comparing pretreatment samples from responders and non-responders, metabolites mainly belonging to amino acid and lipid (i.e., fatty acid) pathways were altered. Furthermore, patients with rapidly progressive disease showed an extensively altered lipid metabolism. Both ATRA and valproic acid monotherapy also altered the amino acid and lipid metabolite profiles; however, these changes were only highly significant for valproic acid treatment. Twenty-three metabolites were significantly altered by seven-day valproic acid treatment (p < 0.05, q < 0.05), where the majority of altered metabolites belonged to lipid (especially fatty acid metabolism) and amino acid pathways, including several carnitines. These metabolomic effects, and especially the effects on lipid metabolism, may be important for the antileukemic and epigenetic effects of this treatment. MDPI 2019-10-10 /pmc/articles/PMC6829623/ /pubmed/31658693 http://dx.doi.org/10.3390/cells8101229 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Grønningsæter, Ida Sofie Fredly, Hanne Kristin Gjertsen, Bjørn Tore Hatfield, Kimberley Joanne Bruserud, Øystein Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy |
title | Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy |
title_full | Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy |
title_fullStr | Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy |
title_full_unstemmed | Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy |
title_short | Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy |
title_sort | systemic metabolomic profiling of acute myeloid leukemia patients before and during disease-stabilizing treatment based on all-trans retinoic acid, valproic acid, and low-dose chemotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829623/ https://www.ncbi.nlm.nih.gov/pubmed/31658693 http://dx.doi.org/10.3390/cells8101229 |
work_keys_str_mv | AT grønningsæteridasofie systemicmetabolomicprofilingofacutemyeloidleukemiapatientsbeforeandduringdiseasestabilizingtreatmentbasedonalltransretinoicacidvalproicacidandlowdosechemotherapy AT fredlyhannekristin systemicmetabolomicprofilingofacutemyeloidleukemiapatientsbeforeandduringdiseasestabilizingtreatmentbasedonalltransretinoicacidvalproicacidandlowdosechemotherapy AT gjertsenbjørntore systemicmetabolomicprofilingofacutemyeloidleukemiapatientsbeforeandduringdiseasestabilizingtreatmentbasedonalltransretinoicacidvalproicacidandlowdosechemotherapy AT hatfieldkimberleyjoanne systemicmetabolomicprofilingofacutemyeloidleukemiapatientsbeforeandduringdiseasestabilizingtreatmentbasedonalltransretinoicacidvalproicacidandlowdosechemotherapy AT bruserudøystein systemicmetabolomicprofilingofacutemyeloidleukemiapatientsbeforeandduringdiseasestabilizingtreatmentbasedonalltransretinoicacidvalproicacidandlowdosechemotherapy |